Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of “Hold” from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned a consensus recommendation of “Hold” from the ten ratings firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $11.33.

ZNTL has been the subject of a number of research analyst reports. Wells Fargo & Company lowered Zentalis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $29.00 to $9.00 in a research report on Tuesday, June 18th. Stifel Nicolaus decreased their target price on Zentalis Pharmaceuticals from $32.00 to $10.00 and set a “buy” rating for the company in a research report on Tuesday, June 18th. UBS Group lowered Zentalis Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $28.00 to $5.00 in a report on Thursday, June 20th. Oppenheimer decreased their price objective on Zentalis Pharmaceuticals from $50.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, June 18th. Finally, Wedbush lowered Zentalis Pharmaceuticals from a “neutral” rating to an “underperform” rating and decreased their price objective for the stock from $15.00 to $4.00 in a report on Tuesday, June 18th.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ:ZNTL opened at $4.19 on Tuesday. The company has a market capitalization of $297.62 million, a price-to-earnings ratio of -1.26 and a beta of 1.71. The business’s 50-day moving average is $9.95 and its 200-day moving average is $12.54. Zentalis Pharmaceuticals has a 1 year low of $3.93 and a 1 year high of $29.04.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.91. The business had revenue of $40.56 million during the quarter, compared to analyst estimates of $35.00 million. During the same period in the prior year, the firm earned ($1.07) earnings per share. Analysts anticipate that Zentalis Pharmaceuticals will post -2.72 EPS for the current year.

Insider Activity

In other news, insider Diana Hausman sold 3,356 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total value of $42,352.72. Following the completion of the transaction, the insider now directly owns 373,876 shares of the company’s stock, valued at $4,718,315.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Diana Hausman sold 3,356 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $12.62, for a total value of $42,352.72. Following the completion of the transaction, the insider now directly owns 373,876 shares of the company’s stock, valued at $4,718,315.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Cam Gallagher sold 9,597 shares of the company’s stock in a transaction that occurred on Friday, May 31st. The shares were sold at an average price of $11.98, for a total value of $114,972.06. Following the completion of the transaction, the chief financial officer now directly owns 633,680 shares of the company’s stock, valued at $7,591,486.40. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. ProShare Advisors LLC lifted its stake in Zentalis Pharmaceuticals by 9.0% in the first quarter. ProShare Advisors LLC now owns 15,436 shares of the company’s stock valued at $243,000 after purchasing an additional 1,274 shares during the last quarter. Exchange Traded Concepts LLC lifted its stake in Zentalis Pharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock valued at $91,000 after purchasing an additional 1,519 shares during the last quarter. Quest Partners LLC purchased a new position in Zentalis Pharmaceuticals in the fourth quarter valued at approximately $38,000. Tower Research Capital LLC TRC lifted its stake in Zentalis Pharmaceuticals by 252.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after purchasing an additional 2,589 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Zentalis Pharmaceuticals by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 445,823 shares of the company’s stock valued at $6,754,000 after purchasing an additional 3,759 shares during the last quarter.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.